Latest Amgen Stories

Neurological Wellness Center Responds to a Recent Report; “Brain Injury Awareness Month: New Hope for the Brain-Injured Person.”* (PRWEB) May 08, 2013 Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from traumatic brain injury since 2010. March was Brain Injury Awareness Month. Traumatic Brain Injury (TBI) is a serious problem in the United States according to this article in the Huffington Post. 1.7 million Americans will experience a...

Study Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting THOUSAND OAKS, Calif., May 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix(®) (panitumumab) versus Erbitux(®) (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint of non-inferiority for overall survival. The...

Neurological Wellness Center to launch a clinical trial of perispinally administered etanercept as an Alzheimer's disease treatment. (PRWEB) May 01, 2013 Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from Alzheimer's disease since 2010. Although the precise causes of Alzheimer's Disease are still unknown, there is a growing body of evidence linking chronic inflammatory events in the brain with the onset and progression of AD....

Amgen's Breakaway from Cancer to Celebrate Cancer Survivors at Every Stage of the Eighth Annual Professional Cycling Race THOUSAND OAKS, Calif., May 1, 2013 /PRNewswire/ -- Amgen today announced that four individuals who are an inspiration and have made a difference for others affected by cancer have been selected as Breakaway from Cancer(®) Champions. They will be honored as part of Amgen's Breakaway from Cancer initiative at the eighth consecutive edition of the Amgen Tour of...

INCLINE VILLAGE, Nev., April 30, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed Peter S. Garcia to the position of vice president, chief financial officer (CFO) and acting chief accounting officer, effective as of May 13, 2013. Mr. Garcia has spent the last 16 years in various CFO positions for biotechnology companies. He joins PDL from BioTime, Inc. (NYSE MKT: BTX) where he served as CFO since 2011. (Logo:...

MISSISSAUGA, ON, April 30, 2013 /CNW/ - Amgen, a biotechnology company developing both innovative biologic and biosimilar medicines, welcomes a new report from the European Commission detailing Europe's strong regulatory and commercial foundation for biosimilars in the healthcare marketplace. The report shows that biosimilars are helping improve competition and thus may be increasing access to biologic medicines for patients. The science-led regulatory framework in the European...

SAN DIEGO, April 22, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that Michael Narachi, president and chief executive officer, has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a term of two years. PhRMA represents the country's leading innovative biopharmaceutical research and...

THOUSAND OAKS, Calif., April 18, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 23, 2013, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Daylight Time. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior...

Neurological Wellness Center Comments on Alzheimer’s Care Assisted Living Expenses Costing $90 to $200 Per Day According to a Recent Article in the Los Angeles Times* (PRWEB) April 17, 2013 Implementing the treatment detailed in Perispinal etanercept: a new therapeutic paradigm in neurology by Dr. Tobinick can enable a severely impaired person needing full time assisted living care who is unable to recognize their own children or even count to ten to, after a single dose, recognize...

Kinaxis customer Amgen to present: "A Journey towards Excellence in Network Planning & Optimization" OTTAWA, Ontario, April 17, 2013 /PRNewswire/ -- Kinaxis®, provider of RapidResponse®, a cloud-based supply chain management (SCM) and sales and operations planning (S&OP) solution, today announced that Elisabeth Kaszas, Director of Supply Chain at Amgen, will present at LogiPharma Europe 2013. The event takes place April 23 - 24, 2013 at Hotel President Wilson, Geneva....